Michael Rosenzweig is an Oncology physician affiliated with City Of Hope National Medical Center. OpenAlex indexes 164 publications with 8,256 citations (h-index 41); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Sponsor: City of Hope Medical Center
- Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
Sponsor: National Cancer Institute (NCI)
- Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Sponsor: City of Hope Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20251 payment
- Janssen Biotech, Inc.Program year202512 payments
- Celgene CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2021–2025 per NIH RePORTER. The latest:
- Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans
Beckman Research Institute/city of Hope
FY2025$677,645R01CA253545 - Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans
Beckman Research Institute/city of Hope
FY2023$653,591R01CA253545 - Repurposing Leflunomide to Delay Progression of Smoldering Multiple Myeloma in African Americans
Beckman Research Institute/city of Hope
FY2022$656,771R01CA253545
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Erminia Massarelli, MD
City Of Hope National Medical Center
Swetha Thiruvengadam, MD
City Of Hope National Medical Center
Yuman Fong, MD
City Of Hope National Medical Center
Ravi Salgia, MD, PhD
City Of Hope National Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”